Literature DB >> 16605241

Inhibition of amyloid fibril formation and cytotoxicity by hydroxyindole derivatives.

Tomer Cohen1, Anat Frydman-Marom, Meirav Rechter, Ehud Gazit.   

Abstract

Gaining insight into the mechanism of amyloid fibril formation, the hallmark of multiple degenerative syndromes of unrelated origin, and exploring novel directions of inhibition are crucial for preventing disease development. Specific interactions between aromatic moieties were suggested to have a key role in the recognition and self-assembly processes leading to the formation of amyloid fibrils by several amyloidogenic polypeptides, including the beta-amyloid polypeptide associated with Alzheimer's disease. Our finding of the high-affinity molecular recognition and intense amyloidogenic potential of tryptophan-containing peptide fragments led to the hypothesis that screening for indole derivatives might lead to the identification of potential inhibitors of amyloid formation. Such inhibitors could mediate specific recognition processes without allowing further growth of the well-ordered amyloid chain. Using fluorescence spectroscopy, atomic force microscopy, and electron microscopy to screen 29 indole derivatives, we identified three potent inhibitors: indole-3-carbinol (I3C), 3-hydroxyindole (3HI), and 4-hydroxyindole (4HI). The latter, a simple low-molecular weight aromatic compound, was the most effective, completely abrogating not only the formation of aggregated structures by Abeta but also the cytotoxic activity of aggregated Abeta toward cultured cells. The results of this study provide further experimental support for the paradigm of amyloid inhibition by heteroaromatic interaction and point to indole derivatives as a simple molecular platform for the development of novel fibrillization inhibitors.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16605241     DOI: 10.1021/bi051525c

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  34 in total

1.  Quantitative structure-activity relationship analysis of β-amyloid aggregation inhibitors.

Authors:  Shiri Stempler; Michal Levy-Sakin; Anat Frydman-Marom; Yaniv Amir; Roni Scherzer-Attali; Ludmila Buzhansky; Ehud Gazit; Hanoch Senderowitz
Journal:  J Comput Aided Mol Des       Date:  2010-12-17       Impact factor: 3.686

2.  Structure-activity relationships in peptide modulators of β-amyloid protein aggregation: variation in α,α-disubstitution results in altered aggregate size and morphology.

Authors:  Cyrus K Bett; Johnpeter N Ngunjiri; Wilson K Serem; Krystal R Fontenot; Robert P Hammer; Robin L McCarley; Jayne C Garno
Journal:  ACS Chem Neurosci       Date:  2010-07-08       Impact factor: 4.418

3.  Cleavage agents for soluble oligomers of human islet amyloid polypeptide.

Authors:  Junghun Suh; Woo Suk Chei; Tae Yeon Lee; Min Gyum Kim; Sang Ho Yoo; Keunhong Jeong; Jae Young Ahn
Journal:  J Biol Inorg Chem       Date:  2008-03-05       Impact factor: 3.358

Review 4.  Self assembly of short aromatic peptides into amyloid fibrils and related nanostructures.

Authors:  Ehud Gazit
Journal:  Prion       Date:  2007-01-02       Impact factor: 3.931

5.  Newfound effect of N-acetylaspartate in preventing and reversing aggregation of amyloid-beta in vitro.

Authors:  Jean-Pierre Dollé; Jeffrey M Rodgers; Kevin D Browne; Thomas Troxler; Feng Gai; Douglas H Smith
Journal:  Neurobiol Dis       Date:  2018-05-31       Impact factor: 5.996

6.  Inhibition of Abeta42 aggregation using peptides selected from combinatorial libraries.

Authors:  Michael Baine; Daniel S Georgie; Elelta Z Shiferraw; Theresa P T Nguyen; Luiza A Nogaj; David A Moffet
Journal:  J Pept Sci       Date:  2009-08       Impact factor: 1.905

7.  Study of cosolvent-induced alpha-chymotrypsin fibrillogenesis: does protein surface hydrophobicity trigger early stages of aggregation reaction?

Authors:  Reza Khodarahmi; Hosnieh Soori; Mojtaba Amani
Journal:  Protein J       Date:  2009-10       Impact factor: 2.371

8.  Atomic-resolution map of the interactions between an amyloid inhibitor protein and amyloid β (Aβ) peptides in the monomer and protofibril states.

Authors:  Moustafa Algamal; Rashik Ahmed; Naeimeh Jafari; Bilal Ahsan; Joaquin Ortega; Giuseppe Melacini
Journal:  J Biol Chem       Date:  2017-08-10       Impact factor: 5.157

9.  Differentiating Alzheimer disease-associated aggregates with small molecules.

Authors:  Nicolette S Honson; Ronald L Johnson; Wenwei Huang; James Inglese; Christopher P Austin; Jeff Kuret
Journal:  Neurobiol Dis       Date:  2007-07-28       Impact factor: 5.996

10.  Complete phenotypic recovery of an Alzheimer's disease model by a quinone-tryptophan hybrid aggregation inhibitor.

Authors:  Roni Scherzer-Attali; Riccardo Pellarin; Marino Convertino; Anat Frydman-Marom; Nirit Egoz-Matia; Sivan Peled; Michal Levy-Sakin; Deborah E Shalev; Amedeo Caflisch; Ehud Gazit; Daniel Segal
Journal:  PLoS One       Date:  2010-06-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.